Fibroblas Terkait Kanker dan Dampaknya terhadap Kelangsungan Hidup Keseluruhan pada Karsinoma Urotelial Kandung Kemih: Suatu Tinjauan Sistematis Cancer-Associated Fibroblasts and Their Impact on Overall Survival in Bladder Urothelial Carcinoma: A Systematic Review
Article Sidebar
Main Article Content
Abstract
Background: Bladder urothelial carcinoma (BUC) remains a common urologic malignancy with substantial mortality. The tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), promotes extracellular matrix remodeling, angiogenesis, immune evasion, and treatment resistance, suggesting CAFs may serve as prognostic and predictive biomarkers. Objective: To evaluate the association between CAFs and overall survival (OS) in BUC and identify clinically relevant CAF-related markers.
Methods: A PRISMA-guided systematic review was performed using PubMed, Cochrane Library, Taylor & Francis, ProQuest, Scopus, and EMBASE (2015–2025). Eligible human studies assessing CAFs/CAF-signatures in BUC were included. Risk of bias was assessed using ROBINS-I.
Results: Nine studies were included. Across cohorts, elevated CAF abundance or CAF-related markers consistently correlated with poorer outcomes. High CAF infiltration in TCGA-BLCA was associated with reduced OS (p=0.003) and advanced stage (p<0.001). Stromal markers such as FAP (HR=2.06) and PDGFRβ (HR=1.75) predicted worse OS, with FAP-dominant phenotypes showing the lowest survival. myCAF- and iCAF-high subtypes were linked to shorter OS (e.g., iCAF cluster p=0.024). Multiple CAF-based gene signatures (e.g., 7-gene models) stratified mortality risk (multivariate HR up to 3.51; AUC 0.88). COL10A1 overexpression also predicted inferior OS. A fibroblast-related gene index (FRGI) showed strong performance in ICI-treated patients (1-year OS AUC=0.95) and was enriched in non-responders.
Conclusion: CAF abundance and subtype composition are robust adverse prognostic indicators in BUC and show promise for risk stratification and treatment decision support, particularly for immunotherapy responsiveness.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Bellmunt, J., Hussain, M., Gschwend, J. E., Albers, P., Dann, J. M., De Santis, M., et al. (2021). Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 22(4), 525–537.
Burley, A., Rullan, A., & Wilkins, A. (2022). A review of the biology and therapeutic implications of cancer-associated fibroblasts in muscle-invasive bladder cancer. Frontiers in Oncology, 12, 1000888.
Chen, H., Yang, W., Xue, X., Li, Y., Jin, Z., & Ji, Z. (2022). Integrated analysis revealed an inflammatory cancer-associated fibroblast-based subtypes with promising implications in predicting the prognosis and immunotherapeutic response of bladder cancer patients. International Journal of Molecular Sciences, 23(24), 15970.
Chen, H., Yang, W., Xue, X., Li, Y., Jin, Z., & Ji, Z. (2022). Integrated analysis revealed an inflammatory cancer-associated fibroblast-based subtypes with promising implications in predicting the prognosis and immunotherapeutic response of bladder cancer patients. International Journal of Molecular Sciences, 23(24), 15970.
Da, Y., Lu, Z., Zhu, Z., Tai, H., Liu, Y., & Zhu, Y. (2025). A high stroma-tumor ratio is associated with an immunosuppressive tumor microenvironment and a poor prognosis in bladder cancer. Frontiers in Oncology, 15, 1604609. https://doi.org/10.3389/fonc.2025.1604609
Du, Y. H., Jiang, X., Wang, B., Cao, J., Wang, Y., Yu, J., Wang, X. Z., & Liu, H. T. (2021). The cancer-associated fibroblasts related gene CALD1 is a prognostic biomarker and correlated with immune infiltration in bladder cancer. Cancer Cell International, 21, 283.
Du, Y. H., Sui, Y. Q., Cao, J., Jiang, X., Wang, Y., Yu, J., Wang, B., Wang, X. Z., & Xue, B. X. (2022). Dynamic changes in myofibroblasts affect the carcinogenesis and prognosis of bladder cancer associated with tumor microenvironment remodeling. Frontiers in Cell and Developmental Biology, 10, 833578.
Koll, F. J., Banek, S., Kluth, L., Mende, C. H., Gontarewicz, A., Dräger, D. L., et al. (2023). Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis. Journal of Translational Medicine, 21(1), 124.
Li, J. X., Kong, Z., Qi, Y. J., Wang, W., Su, Q., Huang, W., Zhang, Z. H., Li, S., & Du, E. (2024). Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8+ T-cell-fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer. International Journal of Surgery, 110, 4911–4931.
Liu, J., Li, C., Huang, K., Zhang, L., Liu, B., Gao, S., et al. (2022). A classification based on tumor-stroma ratio and tumor budding for patients with muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 22(3), 323–330.
Liu, L., Xu, L., Wu, D., Zhu, Y., Li, X., Xu, C., Chen, K., Lin, Y., Lao, J., Cai, P., Li, X., Luo, Y., Li, X., Huang, J., Lin, T., & Zhong, W. (2024). Impact of tumour stroma-immune interactions on survival prognosis and response to neoadjuvant chemotherapy in bladder cancer. eBioMedicine, 104, 105152. https://doi.org/10.1016/j.ebiom.2024.105152
Liu, Y., Jian, J., Zhang, Y., Wang, L., Liu, X., & Chen, Z. (2023). Construction of cancer-associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma. Frontiers in Oncology, 13, 1170893.
Mezheyeuski, A., Segersten, U., Leiss, L. W., Malmström, P.-U., Hatina, J., Östman, A., et al. (2020). Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome. Scientific Reports, 10(1), 281.
Muilwijk, T., Akand, M., Daelemans, S., Marien, K., Waumans, Y., Kockx, M., et al. (2021). Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer. PLOS ONE, 16(9), e0257195.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
Qin, Y., Zu, X., Li, Y., Han, Y., Tan, J., Cai, C., Shen, E., Liu, P., Deng, G., Feng, Z., Wu, W., Peng, Y., Liu, Y., Ma, J., Zeng, S., Chen, Y., & Shen, H. (2023). A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer. iScience, 26(9), 107722. https://doi.org/10.1016/j.isci.2023.107722
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., & Jemal, A. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
Wang, X., Bai, Y., Zhang, F., Li, D., Chen, K., Wu, R., Tang, Y., Wei, X., & Han, P. (2023). Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation. Frontiers in Immunology, 14, 955949.
Wang, X., Bai, Y., Zhang, F., Li, D., Chen, K., Wu, R., Tang, Y., Wei, X., & Han, P. (2023). Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation. Frontiers in Immunology, 14, 955949.
Zhang, M., Zhu, J., Zhang, P., Li, L., Min, M., Li, T., & He, W. (2023). Development and validation of cancer-associated fibroblasts-related gene landscape in prognosis and immune microenvironment of bladder cancer. Frontiers in Oncology, 13, 1174252.
Zheng, Q., Jiang, Z., Ni, X., Yang, S., Jiao, P., Wu, J., Xiong, L., Yuan, J., Wang, J., Jian, J., Wang, L., Yang, R., Chen, Z., & Liu, X. (2023). Machine learning quantified tumor-stroma ratio is an independent prognosticator in muscle-invasive bladder cancer. International Journal of Molecular Sciences, 24(3), 2746. https://doi.org/10.3390/ijms24032746